CNSP · CNS Pharmaceuticals Inc

-

Please sign in to comment on CNSP

1 Comment

Admin

4 years, 10 months ago

CNS Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 17.4% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

CNS Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 18.9% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 41.8% to $-1M since the same quarter in the previous year.

Based on the above factors, CNS Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US18978H1023
Sector	Healthcare
Industry	Biotechnology

PE Ratio	0.0
Target Price	20
Beta	0.41
Market Cap	2M
Dividend Yield	None

ABOUT

CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNSP · CNS Pharmaceuticals Inc

-

CNS Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest CNS Pharmaceuticals Inc using a moving average strategy